Type Code Selection under Nomenclature Order No. 4n in Russia
Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20
1. Key takeaways
The technical starting point of Russian state registration is the selection of a type code (vid meditsinskogo izdeliya) under the nomenclature classification catalogue approved by Order No. 4n of the Ministry of Health (June 6, 2012). Each type code carries its own recommended potential risk application class, and the testing scope follows from that class automatically. In other words, the code chosen at the beginning of the project silently sets the evidence requirements, the expert review fee tier, and much of the dossier structure that follows.
The consequence of choosing the wrong code is severe: the entire registration dossier must be redone, not merely supplemented with an explanatory note. Testing commissioned against the wrong type definition, an expert review conducted under the wrong class, and dossier sections written to the wrong evidence expectations all lose their value the moment the code changes. This is why experienced teams treat type code selection as a deliberative step with its own written record, rather than a lookup exercise completed in an afternoon. A few days of careful analysis at the start protects months of downstream work.
A useful way to manage this risk is to run the selection process with the expert reviewer in mind. The expert institution does not ask what the product is called; it asks how the declared type definition matches what the dossier describes. Where the definition of the chosen type mentions the function, the construction, and the intended use of the product, the mapping is straightforward. Where the product adds an element that the definition does not mention, such as connected software or an accessory that performs its own measurement, the mapping needs an argument. Preparing that argument early, and checking it against the catalogue wording rather than against internal product names, keeps the file aligned with how the review will actually be conducted.
2. Legal basis
| Legal act | Number | Date | Provisions |
|---|---|---|---|
| Order of the Ministry of Health On Approving the Nomenclature Classification of Medical Devices | Order of the Ministry of Health of Russia No. 4n | June 6, 2012 (as subsequently amended) | type names, definitions, and recommended risk classes |
| Federal Law On the Fundamentals of Protection of the Health of Citizens in the Russian Federation | 323-FZ | November 21, 2011 | Article 38, parts 1 and 8 |
| Government Resolution of the Russian Federation On the State Registration Rules for Medical Devices | Government Resolution No. 1684 | November 30, 2024 | para. 5 |
| Decision of the Board of the Eurasian Economic Commission | EEC Decision No. 173 | December 22, 2015 | union classification rules (used for cross-checking) |
3. Expert insights
Insight 1: The catalogue gives descriptions, not product names. Catalogue entries group products by type with generic naming, and the task of the applicant is to map its own product onto the closest type definition. When a product straddles the boundary of several types, as often happens with analyzers that incorporate software, the file should explain the reasoning for the chosen division. If the reasoning is not documented, the expert institution may conclude that the declared subject has drifted, and queries at that stage consume weeks. A short written rationale, prepared before submission, is inexpensive insurance against this class of delay.
Insight 2: The code and the class are bound together. Selecting a code locks in the recommended class, and with it the testing scope and the expert review fee. If a company believes the class has been overestimated, the remedy is to change the type code, or to seek a determination under EEC Decision No. 173 in the union framework, rather than attempting to argue the class down during filing. Attempts to quietly register a class 2b device under a class 1 code are detected during expert review and damage the credibility of the entire application, including the parts that were properly prepared.
Insight 3: TN VED and OKPD 2 codes are not classification tools. These two coding systems serve customs and tax purposes and cannot be used in reverse to determine the medical device type code. However, in scenarios involving VAT exemption, customs classification, and verification checks, the three code sets must be cross-consistent, as examined in detail in article 40 of this series. Discrepancies between the registration record and the commercial codes trigger questions from customs and tax authorities even when the registration itself is entirely valid.
4. Practical recommendations
- Validate the selection against three sources simultaneously: the catalogue entry of Order No. 4n, the classification rules of Decision No. 173, and the Russian-language intended-purpose wording of the product itself. All three must point to the same type.
- Write the selection rationale and the class argument as a standalone document and place it in the dossier, so it can be reused during later amendments and during conversion to the union pathway without re-analysis.
- On model strategy, all models within one registration unit should share a single type code; product lines that cross type codes are better filed as separate applications rather than forced into one dossier.
- Revisit the selected code whenever the product configuration, software functionality, or intended-purpose wording changes, because such changes can move the product to a neighboring type with a different class.
5. Verification checklist
- □ The target type code in the catalogue of Order No. 4n has been determined and its full definition transcribed
- □ The selection rationale has been documented, including an explanation of why the product does not fall into neighboring types
- □ The recommended class attached to the code is consistent with the project budget assumptions
- □ All models within the same registration unit share the same type code
- □ The TN VED and OKPD 2 codes and the type code conclusion are consistent across commercial documents
GRZAN supports manufacturers through type code selection and the classification work that surrounds it, combining the catalogue of Order No. 4n, the rules of EEC Decision No. 173, and careful review of Russian-language intended-purpose statements. Our team prepares the written selection rationale required by expert institutions, aligns commercial coding with the registration record, and structures dossiers so that later amendments and union conversion proceed without rework. For nomenclature classification and RZN registration support in Russia, contact GRZAN at info@grzanglobal.com.
Regulatory information verified as of October 29, 2026.
Disclaimer
Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.
About GRZAN
GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.
GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.
Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.
What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.
Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.
Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.
Take your devices global with GRZAN
We work with manufacturers worldwide to open new markets with a clear regulatory pathway.
Contact us